During 2025, the global Healthcare and Life Sciences R&D partnerships shifted clearly toward value over volume. Deal count declined to 685 from 753 in 2024, but total announced value increased to $273.6 billion, and upfront payments rose to $18.6 billion, reflecting stronger confidence in high-value assets and platform-driven innovation. Regional trends diverged, with the U.S. recording 306 deals and $96.8 billion in value despite lower activity, EMEA delivering 164 deals totaling $43.2 billion with richer deal economics, and APAC emerging as the key growth engine as deal volume rose to 201 and total value more than doubled to $132.6 billion.
Activity was led by large, platform-centric transactions across oncology, immunology, cardiovascular, and metabolic diseases. Notable deals included XtalPi and DoveTree’s AI-enabled molecular glue collaboration with $51 million upfront and up to $5.9 billion in milestones; Monte Rosa Therapeutics and Argo Biopharma’s high value partnerships with Novartis, each featuring $120-160 million upfront and milestone potential exceeding $5 billion; AstraZeneca’s AI-driven discovery alliance with CSPC Pharmaceuticals with $110 million upfront and up to $5.2 billion in milestones; and the largest transaction, Zealand Pharma’s obesity partnership with Roche, anchored by $1.7 billion upfront, up to $3.6 billion in milestones, profit sharing in the U.S. and Europe.
In 2025, global Healthcare and Life Sciences R&D partnership activity declined in volume but strengthened in value. Deal count fell to 685 from 753 in 2024, while total announced value increased to $273.6 billion from $202.8 billion. Upfront cash and equity commitments rose to $18.6 billion from $14.4 billion, indicating a greater willingness by partners to deploy capital earlier and support higher-quality assets. Average deal value increased to $956 million in 2025 from $674 million in 2024, and the median rose to $566 million from $360 million. This shift suggests value expansion was broad-based rather than driven by a small number of outlier transactions. Across 2024 and 2025 combined, the sector delivered 1,438 partnerships representing $476.3 billion in total announced value and $32.9 billion in upfront consideration.
US Healthcare & Life Sciences – R&D Partnerships
In 2025, U.S. Healthcare and Life Sciences R&D partnership activity declined in volume and aggregate value. Deal count fell to 306 from 404 in 2024, total announced value decreased to $96.8 billion from $112.8 billion, and upfront cash and equity commitments declined to $5.8 billion from $7.2 billion. Despite this slowdown, deal quality improved. Average deal value increased to $787 million from $680 million, while the median rose to $485 million from $303 million, indicating that higher-value transactions were more common. Across 2024 and 2025, the U.S. recorded 710 partnerships with $209.6 billion in total announced value and $13 billion in upfront consideration,
EMEA Healthcare & Life Sciences – R&D Partnerships
In 2025, EMEA Healthcare and Life Sciences R&D partnership also declined discreetly to 164 deals from 176 in 2024, but deal value and upfront commitments increased materially. Total announced value rose to $43.2 billion from $31 billion, while upfront cash and equity increased to $5.1 billion from $4.1 billion, reflecting stronger collaboration economics despite fewer transactions. Deal sizes expanded significantly, with average deal value increasing to $848 million from $508 million and the median rising to $493 million from $294 million. This indicates a broad-based shift toward higher-value partnerships rather than gains driven by a small number of large transactions. Across 2024 and 2025, the EMEA region recorded 340 partnerships, totaling $74.2 billion in announced value and $9.1 billion in upfront consideration.
Â
APAC Healthcare & Life Sciences – R&D Partnerships
In 2025, APAC Healthcare and Life Sciences R&D partnership activity accelerated across both volume and value. Deal count increased to 201 from 154 in 2024, while total announced value more than doubled to $132.6 billion from $58.7 billion. Upfront cash and equity commitments also rose sharply to $7.6 billion from $3.1 billion, reflecting stronger near-term capital deployment alongside higher activity levels. Deal sizes expanded materially, with average deal value increasing to $1.3 billion from $803 million and the median rising to $745 million from $449 million. This growth was broad-based, rather than driven by a small number of large transactions. Across 2024 and 2025, the APAC region recorded 355 partnerships, totaling $191.3 billion in announced value and $10.7 billion in upfront consideration.
Â
R&D Partnerships with $100M+ Upfront Cash & Equity
In 2025, global Healthcare and Life Sciences R&D partnerships with upfront payments of $100 million or more for Phase III and earlier assets increased in both frequency and scale. Deal count rose to 39 from 33 in 2024, while total announced value expanded to $109.4 billion from $74.1 billion. Upfront cash and equity commitments increased to $12.9 billion from $9.8 billion, reflecting a greater willingness to deploy substantial capital earlier in development. Deal sizes moved higher across the board, with average deal value rising to $2.8 billion from $2.2 billion and the median increasing to $2 billion from $1.7 billion. This indicates a broad-based shift toward higher-value, premium partnerships rather than growth driven by a small number of outlier transactions. Across 2024 and 2025, this high-upfront segment comprised 72 deals with $183.5 billion in total announced value and $22.8 billion in upfront consideration.
 Â
Number of Deals by Range of Upfront
In 2025, global Healthcare and Life Sciences R&D partnerships shifted toward larger upfront commitments. The number of small upfront deals of $10 million or less remained unchanged at 34, while mid-tier deals with $10 million to $100 million upfront declined to 98 from 106. In contrast, large upfront deals exceeding $100 million increased to 39 from 33, indicating a clear upward shift in upfront deal structures. Across 2024 and 2025 combined, the market recorded 68 deals with upfront payments of $10 million or less, 204 deals in the $10 million to $100 million range, and 72 deals above $100 million.
 Â
R&D Partnerships by Subsector
In 2025, global Healthcare and Life Sciences R&D partnership value was heavily concentrated in Therapeutic Platforms and Biopharma, which accounted for $221.9 billion of the $273.6 billion total. Diagnostics, sequencing, omics, and tools contributed $45.9 billion, while Manufacturing Tech and other areas totaled $4.3 billion, and Medtech, devices, digital therapeutics, and wearables remained limited at $1.5 billion. The same subsector ranking held in 2024 but at lower levels, with Therapeutic Platforms and Biopharma generating $162.7 billion, Diagnostics and Omics $26.8 billion, Manufacturing Tech and Others $12.9 billion, and Medtech and Digital $300 million, aligning with the $202.8 billion total. Across 2024 and 2025 combined, the market delivered $384.6 billion in Biopharma partnership value, $72.7 billion in Diagnostics and Omics, $17.2 billion in Manufacturing Tech and Others, and $1.8 billion in Medtech and Digital. The increase in overall market value in 2025 was driven primarily by larger Biopharma collaborations, up $59.2 billion year over year, and stronger Diagnostics and Omics activity, up $19.1 billion, partly offset by an $8.6 billion year-over-year decline in Manufacturing Tech and Other deals.
In 2025, global Healthcare and Life Sciences R&D partnership activity remained concentrated in Therapeutic Platforms and Biopharma, which recorded 453 deals, down from 469 in 2024 (-16 deals). Diagnostics, sequencing, omics, and tools accounted for a decline of 175 deals, declining from 197 (-22), while Manufacturing Tech and Other areas recorded 43 deals, down from 55 (-12). Medtech, devices, digital therapeutics, and wearables saw the sharpest contraction, falling to 14 deals from 32 in 2024 (-18). Across 2024 and 2025 combined, the market delivered 922 Biopharma partnerships, 372 Diagnostics and Omics partnerships, 98 Manufacturing Tech and Other partnerships, and 46 Medtech and Digital partnerships. Overall, the pullback in 2025 deal volume was broad-based across all subsectors, with the largest absolute declines in Diagnostics and Omics, as well as Medtech and Digital, even as overall partnership values increased in 2025.
Prominent Healthcare and Life Sciences R&D Partnerships in 2025
XtalPi development and commercialization deal with DoveTree – August 2025
XtalPi granted DoveTree exclusive worldwide rights to develop and commercialize molecular glue therapies targeting cancer, inflammation, neurologic, and metabolic diseases. The collaboration combines XtalPi’s AI-driven drug discovery platform with DoveTree’s biological expertise and R&D capabilities. XtalPi will receive $51 million upfront, up to $49 million in near-term payments, and up to $5.9 billion in development and commercial milestones, in addition to tiered royalties.
Monte Rosa Therapeutics license option deal with Novartis – September 2025
Monte Rosa Therapeutics granted Novartis an exclusive, worldwide, sublicensable, and transferable option to discover and develop molecular glue degraders for autoimmune diseases using Monte Rosa’s AI/ML-enabled QuEEN platform, building on their prior VAV1 partnership. Monte Rosa will fund research, while Novartis will handle development and commercialization. Monte Rosa will receive $120 million upfront, up to $60 million in option maintenance payments, up to $180 million in preclinical milestones and option exercise payments, and up to $2.2 billion in development and regulatory milestones, plus $3.2 billion in commercial milestones across licensed products, with royalties ranging from high single-digit to low double-digit percentages. The partnership accelerates access to hard-to-drug immune targets, strengthens Monte Rosa’s financial position, and advances its pipeline toward Phase II trials.
Argo Biopharma license option deal with Novartis – September 2025
Argo Biopharma granted Novartis worldwide (ex-China) rights to develop and commercialize its Phase II ANGPTL3 candidate, two additional molecules for severe hypertriglyceridemia and mixed dyslipidemia, and one siRNA candidate in IND-enabling studies. Argo retains first negotiation rights to BW-00112 and profit-and-loss options in the U.S., with Novartis holding rights ex-China and a P&L split option in China. Argo will receive $160 million upfront, an equity investment, and is eligible for up to $5.2 billion in development and commercial milestones plus tiered royalties.
AstraZeneca research partnership with CSPC Pharmaceuticals – June 2025
AstraZeneca entered a research partnership with CSPC Pharmaceuticals to develop multiple oral candidates, including a preclinical small molecule therapy for immunological and other chronic diseases. CSPC will conduct research in Shijiazhuang using its AI-driven dual-engine drug discovery platform, while AstraZeneca holds an exclusive option to license the program. CSPC will receive $110 million upfront and is eligible for up to $1.6 billion in development milestones, up to $3.6 billion in sales milestones, plus single-digit royalties.
Zealand Pharma co-development and co-commercialization deal with Roche – March 2025
Zealand Pharma granted Roche exclusive worldwide rights to co-develop and co-commercialize petrelintide, an amylin analog for obesity, both as a standalone therapy and in combination with Roche’s dual GLP-1/GIP agonist CT-388. Roche will commercialize globally outside the US and Europe, while both companies will co-commercialize in the US and Europe with a 50/50 profit-and-loss split. Zealand received $1.7 billion upfront, including $1.4 billion at closing, plus eligibility for up to $1.2 billion in development milestones and $2.4 billion in commercial milestones, alongside tiered double-digit royalties in ROW. Roche will receive $350 million from Zealand for the development of combination or next-generation products. The deal was closed on May 9, 2025.
Also check out Global Healthcare and Life Sciences – 2025 Review
